Home Diabetes and Endocrinology Automated Diabetic Macular Ischemia Algorithm Predicts Retinopathy Progression

Automated Diabetic Macular Ischemia Algorithm Predicts Retinopathy Progression

DMI algorithm using optical coherence tomography angiography images predicts diabetic retinopathy progression, DME development, visual acuity deterioration

By Elana Gotkine HealthDay Reporter

WEDNESDAY, May 31, 2023 (HealthDay News) — For patients with diabetes, an automated binary diabetic macular ischemia (DMI) algorithm using optical coherence tomography angiography (OCTA) images predicts diabetic retinal disease progression and deterioration of visual acuity (VA), according to a study published online May 25 in JAMA Ophthalmology.

Dawei Yang, Ph.D., from the Chinese University of Hong Kong, and colleagues conducted a cohort study to examine whether an automated binary DMI algorithm using OCTA images provides prognostic value for diabetic retinopathy (DR) progression, diabetic macular edema (DME) development, and VA deterioration in patients with diabetes. A previously developed deep learning algorithm was used to evaluate DMI assessment of superficial capillary plexus and deep capillary plexus OCTA images.

The analysis included 321 eyes from 178 patients. The researchers found that 32.71, 10.28, and 21.18 percent of eyes had DR progression, developed DME, and had VA deterioration, respectively, during a median follow-up of 50.41 months. The presence of superficial capillary plexus-DMI and deep capillary plexus-DMI at baseline was associated significantly with DR progression (hazard ratios, 2.69 and 3.21, respectively); the presence of deep capillary plexus-DMI was also associated with DME development and VA deterioration (hazard ratios, 4.60 and 2.12, respectively), after adjustment for multiple confounding variables.

“Our findings might provide insights for incorporating both OCTA and artificial intelligence to early detect DMI and further enhance DR management,” the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Copyright © 2023 HealthDay. All rights reserved.